Home > Back to Publisher > Report Information

Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017

GlobalData
September 5, 2011
104 Pages - SKU: GBDT6518412

Abstract Table of Contents Search inside this report Related Reports

Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Pneumococcal Infections market. The report identifies the key trends shaping and driving the global Pneumococcal Infections market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Pneumococcal Infections sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Pneumococcal Infections market. Its scope includes -

Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Pneumococcal Infections market revenues data from 2005 to 2009, forecast for eight years to 2017.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
Analysis of the current and future competition in the seven key countries Pneumococcal Infections market.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Pneumococcal Infections market.
Analysis of key recent licensing and partnership agreements in Pneumococcal Infections market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global Pneumococcal Infections Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Pneumococcal Infections market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global Pneumococcal Infections market landscape? - Identify, understand and capitalize.

1 Table of contents: 1.1 List of Tables; 1.2 List of Figures
2 Pneumococcal Infections - Introduction: 2.1 Disease Overview; 2.2 Epidemiology; 2.3 Etiology and Pathophysiology; 2.4 Signs and Symptoms; 2.5 Diagnosis; 2.6 Treatment and Management Options; 2.7 GlobalData Pipeline Report Guidance
3 Pneumococcal Infections Therapeutics - Market Characterization: 3.1 Pneumococcal Infections Market Size (2005-2010) - Global; 3.2 Pneumococcal Infections Market Forecast (2010-2017) - Global; 3.3 Pneumococcal Infections Market Size (2005-2010) - The US; 3.4 Pneumococcal Infections Market Forecast (2010-2017) - The US; 3.5 Pneumococcal Infections Market Size (2005-2010) - France; 3.6 Pneumococcal Infections Market Forecast (2010-2017) - France; 3.7 Pneumococcal Infections Market Size (2005-2010) - Germany; 3.8 Pneumococcal Infections Market Forecast (2010-2017) - Germany; 3.9 Pneumococcal Infections Market Size (2005-2010) - Italy; 3.10 Pneumococcal Infections Market Forecast (2010-2017) - Italy; 3.11 Pneumococcal Infections Market Size (2005-2010) - Spain; 3.12 Pneumococcal Infections Market Forecast (2010-2017) - Spain; 3.13 Pneumococcal Infections Market Size (2005-2010) - The UK; 3.14 Pneumococcal Infections Market Forecast (2010-2017) - The UK; 3.15 Pneumococcal Infections Market Size (2005-2010) - Japan; 3.16 Pneumococcal Infections Market Forecast (2010-2017) - Japan; 3.17 Drivers and Barriers for the Pneumococcal Infections Market; 3.18 Opportunity and Unmet Need Analysis; 3.19 Key Takeaway
4 Pneumococcal Infections - Competitive Assessment: 4.1 Overview; 4.2 Product Profiles for Major Marketed Products in the Pneumococcal Infections Market; 4.3 Comparison of Pneumococcal Infections Vaccines; 4.4 Key Takeaway
5 Pneumococcal Infections - Pipeline Assessment: 5.1 Overview; 5.2 Strategic Pipeline Assessment; 5.3 Pneumococcal Infections Pipeline - Pipeline by Phases of Development; 5.4 Pneumococcal Infections Market - Clinical Pipeline by Mechanism of Action; 5.5 Pneumococcal Infections - Promising Drugs under Clinical Development; 5.6 Molecule Profile for Promising Drugs under Clinical Development; 5.7 Key Takeaway
6 Pneumococcal Infections - Clinical Trials Mapping: 6.1 Clinical Trials by Region/Country (US, EU5 and Japan); 6.2 Clinical Trials by Phase; 6.3 Clinical Trials by Trial Status; 6.4 Prominent Sponsors; 6.5 Top Companies Participating in Pneumococcal Infections Clinical Trials
7 Pneumococcal Infections - Strategic Assessment: 7.1 Key Events Affecting the Future Market; 7.2 Pneumococcal Infections - Implications for Future Market Competition
8 Pneumococcal Infections - Future Players: 8.1 Introduction; 8.2 Company Profiles
9 Pneumococcal Infections - Licensing and Partnership Deals
10 Pneumococcal Infections - Appendix: 10.1 Market Definitions; 10.2 Abbreviationsl; 10.3 Research Methodology; 10.4 Contact Us; 10.5 Disclaimer; 10.6 Bibliography
1.1 List of Tables: Table 1: Types of Pneumococcal Infections; Table 2: Signs and Symptoms of Common Pneumococcal Infections; Table 3: Treatment for Pneumococcal Infections; Table 4: Pneumococcal Infections Market, Global, Revenue ($m), 2005-2010; Table 5: Pneumococcal Infections Market, Global, Forecast ($m), 2010-2017; Table 6: Pneumococcal Infections Market, The US, Revenue ($m), 2005-2010; Table 7: Pneumococcal Infections Market, The US, Forecast ($m), 2010-2017; Table 8: Pneumococcal Infections Market, France, Revenue ($m), 2005-2010; Table 9: Pneumococcal Infections Market, France, Forecast ($m), 2010-2017; Table 10: Pneumococcal Infections Market, Germany, Revenue ($m), 2005-2010; Table 11: Pneumococcal Infections Market, Germany, Forecast ($m), 2010-2017; Table 12: Pneumococcal Infections Market, Italy, Revenue ($m), 2005-2010; Table 13: Pneumococcal Infections Market, Italy, Forecast ($m), 2010-2017; Table 14: Pneumococcal Infections Market, Spain, Revenue ($m), 2005-2010; Table 15: Pneumococcal Infections Market, Spain, Forecast ($m), 2010-2017; Table 16: Pneumococcal Infections Market, The UK, Revenue ($m), 2005-2010; Table 17: Pneumococcal Infections Market, The UK, Forecast ($m), 2010-2017; Table 18: Pneumococcal Infections Market, Japan, Revenue ($m), 2005-2010; Table 19: Pneumococcal Infections Market, Japan, Forecast ($m), 2010-2017; Table 20: Pneumococcal Infection Therapeutics - Penicillin Antibiotics by Classification, 2011; Table 21: Cure Rates of Zyvox in Nosocomial Pneumonia (%), 2011; Table 22: Cure Rates of Zyvox in Community-Acquired Pneumonia due to MDRSP (%), 2011; Table 23: Pneumococcal Vaccines; Table 24: Pneumococcal Infections - Regulatory Filed Products, 2011; Table 25: Pneumococcal Infections - Phase III Pipeline, 2011; Table 26: Pneumococcal Infections - Phase II Pipeline, 2011; Table 27: Pneumococcal Infections - Phase I Pipeline, 2011; Table 28: Pneumococcal Infections Therapeutics - Discovery and Pre-Clinical Pipeline, 2011; Table 29: Pneumococcal Infections - Most Promising Drugs Under Clinical Development, 2011; Table 30: Status of Ceftobiprole; Table 31: Pneumococcal Infections - Clinical Trials by Country, 2011; Table 32: Pneumococcal Infections - Clinical Trials by Phase, 2011; Table 33: Pneumococcal Infections - Clinical Trials by Status, 2011; Table 34: Pneumococcal Infections - Prominent Sponsors, 2011; Table 35: Pneumococcal Infections - Top Companies Participating in Therapeutics Clinical Trials, 2011; Table 36: GlaxoSmithKline Plc. - Infectious Diseases, Pipeline, 2011; Table 37: Merck &Co. Infectious Diseases, Pipeline, 2011; Table 38: Pfizer - Infectious Disease , Pipeline, 2011; Table 39: Trius Therapeutics-Infectious Disease , Pipeline, 2011; Table 40: Furiex Pharmaceuticals-Infectious Disease , Pipeline, 2011; Table 41: Theravance Inc. - Infectious Disease , Pipeline, 2011; Table 42: Cempra Pharmaceuticals- Infectious Disease , Pipeline, 2011; Table 43: Advanced Life Sciences Holdings ,Inc - Infectious Disease , Pipeline, 2011; Table 44: Basilea Pharmaceutica - Infectious Disease , Pipeline, 2011; Table 45: Pneumococcal Infections Market - Future Players; Table 46: Pneumococcal Infections, Global, Deals, 2011
1.2 List of Figures: Figure 1: Risk of Pneumococcal Infection; Figure 2: Pneumococcal Infections Prophylactic Market, Global, Revenue ($m), 2005-2010; Figure 3: Pneumococcal Infections Therapeutics Market, Global, Revenue ($m), 2005-2010; Figure 4: Pneumococcal Infections Prophylactic Market, Global, Forecast ($m), 2010-2017; Figure 5: Pneumococcal Infections Therapeutics Market, Global, Forecast ($m), 2010-2017; Figure 6: Pneumococcal Infections Prophylactic Market, The US, Revenue ($m), 2005-2010; Figure 7: Pneumococcal Infections Therapeutics Market, The US, Revenue ($m), 2005-2010; Figure 8: Pneumococcal Infections Prophylactic Market, The US, Forecast ($m), 2010-2017; Figure 9: Pneumococcal Infections Therapeutics Market, The US, Forecast ($m), 2010-2017; Figure 10: Pneumococcal Infections Prophylactic Market, France, Revenue ($m), 2005-2010; Figure 11: Pneumococcal Infections Therapeutics Market, France, Revenue ($m), 2005-2010; Figure 12: Pneumococcal Infections Prophylactic Market, France, Forecast ($m), 2010-2017; Figure 13: Pneumococcal Infections Therapeutics Market, France, Forecast ($m), 2010-2017; Figure 14: Pneumococcal Infections Prophylactic Market, Germany , Revenue ($m), 2005-2010; Figure 15: Pneumococcal Infections Therapeutics Market, Germany , Revenue ($m), 2005-2010; Figure 16: Pneumococcal Infections Prophylactic Market, Germany , Forecast ($m), 2010-2017; Figure 17: Pneumococcal Infections Therapeutics Market, Germany , Forecast ($m), 2010-2017; Figure 18: Pneumococcal Infections Prophylactic Market, Italy, Revenue ($m), 2005-2010; Figure 19: Pneumococcal Infections Therapeutics Market, Italy, Revenue ($m), 2005-2010; Figure 20: Pneumococcal Infections Prophylactic Market, Italy, Forecast ($m), 2010-2017; Figure 21: Pneumococcal Infections Therapeutics Market, Italy, Forecast ($m), 2010-2017; Figure 22: Pneumococcal Infections Prophylactic Market, Spain, Revenue ($m), 2005-2010; Figure 23: Pneumococcal Infections Therapeutics Market, Spain, Revenue ($m), 2005-2010; Figure 24: Pneumococcal Infections Prophylactic Market, Spain, Forecast ($m), 2010-2017; Figure 25: Pneumococcal Infections Therapeutics Market, Spain, Forecast ($m), 2010-2017; Figure 26: Pneumococcal Infections Prophylactic Market, The UK, Revenue ($m), 2005-2010; Figure 27: Pneumococcal Infections Therapeutics Market, The UK, Revenue ($m), 2005-2010; Figure 28: Pneumococcal Infections Prophylactic Market, The UK, Forecast ($m), 2010-2017; Figure 29: Pneumococcal Infections Therapeutics Market, The UK, Forecast ($m), 2010-2017; Figure 30: Pneumococcal Infections Prophylactic Market, Japan, Revenue ($m), 2005-2010; Figure 31: Pneumococcal Infections Therapeutics Market, Japan, Revenue ($m), 2005-2010; Figure 32: Pneumococcal Infections Prophylactic Market, Japan, Forecast ($m), 2010-2017; Figure 33: Pneumococcal Infections Therapeutics Market, Japan, Forecast ($m), 2010-2017; Figure 34: Opportunity and Unmet Need in the Pneumococcal Infections Prophylactic Market; Figure 35: Opportunity and Unmet Need in the Pneumococcal Infections Therapeutics Market; Figure 36: Pneumococcal Infections Prophylactic - Strategic Competitor Assessment, 2011; Figure 37: Pneumococcal Infections Therapeutics - Strategic Competitor Assessment, 2011; Figure 38: Pneumococcal Infections - Pipeline by Phase of Development (%), 2011; Figure 39: Pneumococcal Infections - Technology Trends Analytics Framework, 2011; Figure 40: Pneumococcal Infections - Technology Trends Analytics Framework - Description, 2011; Figure 41: Pneumococcal Infections - Pipeline by Mechanism of Action (%), 2011; Figure 42: Pneumococcal Infections - Clinical Trials by Country, 2011; Figure 43: Pneumococcal Infections - Clinical Trials by Phase (%), 2011; Figure 44: Pneumococcal Infections - Clinical Trials by Status (%), 2011; Figure 45: Pneumococcal Infections - Overall Sponsors (%), 2011; Figure 46: Pneumococcal Infections - Prominent Sponsors (%), 2011; Figure 47: Pneumococcal Infections - Top Companies Participating in Therapeutics Clinical Trials, 2011; Figure 48: Pneumococcal Infections Market, Drivers and Restraints, 2011; Figure 49: Implications for Future Market Competition in the Pneumococcal Infections Market, 2011; Figure 50: Pneumococcal Infections Therapeutics Market - Pipeline by Company, 2011; Figure 51: GlobalData Market Forecasting Model

Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017

Share this report

Other tasks

Research Assistance

Related Markets

Infectious Diseases Reports

Free Alert Me service